Codexis Inc (CDXS) Quote

Milestone news today. Company achieved gram scale synthesis which means it is alone in breaking through to large volume production of enzymes. And they monetized an asset with Aldevron. Nestle deal still to come. 40 more in the pipeline. After ARKK's divestiture drove the price into the ground, this should get the stock price back to $6 soon (imo). DYODD

CDXS under $2

Codexis Inc NASDAQ: CDXS

GoSymbol lookup
Health Care : Life Sciences Tools & Services | Small Cap BlendCompany profile
Codexis, Inc. is an enzyme engineering company. The Company is engaged in discovering, developing and selling enzymes and other proteins. The Company commercializes its CodeEvolver enzyme engineering technology platform and products in the manufacture of small molecule pharmaceuticals. It operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Performance Enzymes segment consists primarily of two focus areas: biocatalysts for the sustainable manufacturing of pharmaceuticals, and enzymes for life science applications, including genomic sequencing and nucleic acid synthesis. The Novel Biotherapeutics segment offers product candidates include enzymes that are orally administered for function in the gastrointestinal tract (GI), such as its partnered product candidates CDX-7108 for the treatment of exocrine pancreatic insufficiency and CDX-6114 for the treatment of phenylketonuria, which are both in Phase I clinical trials.

Codexis Inc NASDAQ: CDXS

GoSymbol lookup
Health Care : Life Sciences Tools & Services | Small Cap BlendCompany profile
Codexis, Inc. is an enzyme engineering company. The Company is engaged in discovering, developing and selling enzymes and other proteins. The Company commercializes its CodeEvolver enzyme engineering technology platform and products in the manufacture of small molecule pharmaceuticals. It operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Performance Enzymes segment consists primarily of two focus areas: biocatalysts for the sustainable manufacturing of pharmaceuticals, and enzymes for life science applications, including genomic sequencing and nucleic acid synthesis. The Novel Biotherapeutics segment offers product candidates include enzymes that are orally administered for function in the gastrointestinal tract (GI), such as its partnered product candidates CDX-7108 for the treatment of exocrine pancreatic insufficiency and CDX-6114 for the treatment of phenylketonuria, which are both in Phase I clinical trials.

Cathie Wood can't be the only one to see why this company is so promising. Why are so few others paying attention? When I have available capital I will be taking a position here. I like this company.

tax rules claim first casualty

Better Synthetic Biology Stock: Amyris vs. Codexis

CDXS buy 15.50

another good stock for covered calls
SCTR rating strongly above 50
obv and acc/dist trending higher nicely
uptrending and the macd histogram just crossed up while the macd above 0
stochastics crossing up also
next rally starting























normal chart




log chart

https://www.streetinsider.com/dr/news.php?id=13930511&gfv=1
Check of the EXHIBIT INDEX!

Nice day CDXS. Keep them coming!

Codexis Appoints Molecular Diagnostics Industry Veteran Shawn Clairmont to Lead High-Performance Enzymes Commercialization
February 15, 2018 | About: CDXS +0%
REDWOOD CITY, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the appointment of Shawn Clairmont to the newly created position of Senior Director, Molecular Diagnostics. Codexis is expanding into the molecular diagnostics industry by developing and commercializing high-performance enzymes for use in next generation sequencing (NGS) and polymerase chain reaction (PCR/qPCR) applications. Clairmont will be responsible for all commercial activities related to the molecular diagnostics enzyme product line, including product launches and market and pricing strategies. She reports to Michael Aldridge, Codexis’ Senior VP Corporate & Strategic Development.



“We welcome Shawn to Codexis as we prepare to commercially launch our first high-performance enzymes for the molecular diagnostics industry,” said Aldridge. “Shawn brings us significant global experience in product launches and commercial account management as well as established relationships with key molecular diagnostic firms and industry opinion leaders. We look forward to calling upon her expertise in developing successful strategies as we bring new enzymes into this established market.”

Warning! GuruFocus has detected 6 Warning Signs with CDXS. Click here to check it out.
CDXS 30-Year Financial Data
The intrinsic value of CDXS
Peter Lynch Chart of CDXS
“This is an exciting time in molecular diagnostics as new technologies, such as liquid biopsy, create the need for high-performance enzymes,” said Clairmont. “Codexis is uniquely positioned to use its CodeEvolver® protein engineering platform to develop enzymes aimed at improving the sensitivity and precision of these tests in identifying biomarkers of interest. I’m delighted to join the Codexis team.”

Clairmont has 13 years of molecular diagnostics industry experience. Most recently she served as Chief Operating Officer of BRIDGenomics, a molecular diagnostics and medical device marketing consultancy providing business development and strategic marketing expertise. She previously served for eight years at the molecular diagnostics company QIAGEN in a variety of positions with increasing responsibility, most recently as Director of Sales, America, on the Global Advanced Molecular Pathology Team. Prior to QIAGEN, Clairmont was a technical marketing representative and account manager at bioArray Solutions LTD. She holds an MBA from the College of Saint Scholastica in Duluth, Minn. and a BA in biology from Saint Olaf College in Northfield, Minn.

About Codexis, Inc.

Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.

Codexis Reports Financial Results for the Third Quarter of 2017
Nov. 9, 2017 4:05 PM
Product sales increase 71% over the prior year
Affirms 2017 revenue guidance
Conference call begins at 4:30 pm Eastern time today
REDWOOD CITY, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Codexis, Inc. (CDXS), a leading protein engineering company, announces financial results for the three and nine months ended September 30, 2017, and provides a business update.
“We continue to deliver excellent results in 2017, highlighted by the creation of our new partnership with Nestlé Health Science, as well as a solid financial performance,” said Codexis President and CEO John Nicols. “Our recently announced strategic collaboration with Nestlé Health Science validates the use of our CodeEvolver® protein engineering technology platform for biotherapeutic drug discovery and demonstrates our ability to partner with yet another of the world’s leading companies. Regarding the third quarter financial results, once again we are most proud of the growth in product sales, which increased 71% for the third quarter and 73% year-to-date, with gross margin on product sales again toward the high end of our guidance range.
“Collaboration efforts with Nestlé Health Science have already begun and are expected to contribute significantly to our fourth quarter revenues,” he added. “Together with continued strength in product sales, our fourth quarter is set up to produce the highest revenue quarter for the year and we are reaffirming our total revenue guidance for 2017 of $50 million to $53 million. Delivering on our 2017 revenue guidance will be an exceptional accomplishment by the Codexis team, especially given that over $20 million of last year’s revenues were from non-recurring milestone payments and deferred revenues related to the completion of our two pharmaceutical partners’ platform license technology transfers. The new 2017 revenue sources that offset those headwinds continue to gain momentum as we end this year, setting us up for double-digit revenue growth in 2018.”
Third Quarter Financial Highlights
Total revenues for the third quarter of 2017 were $10.0 million compared with $14.9 million for the third quarter of 2016. The prior year period included the recognition of an $8.0 million milestone payment and $0.6 million in deferred revenue under the platform licensing deal with Merck. Product sales for the third quarter of 2017 increased 71% to $6.9 million from $4.1 million for the prior-year period, primarily due to higher demand for enzymes. Research and development service revenues for the third quarter of 2017 were $2.9 million compared with $10.4 million for the third quarter of 2016, which included $8.6 million of revenue from Merck described above. Revenue from the revenue-sharing arrangement with Exela PharmSci for sales of the argatroban injectable drug was $0.1 million for the third quarter of 2017 compared with $0.4 million for third quarter of 2016.
Gross margin on product sales for the third quarter of 2017 increased to 43% from 32% for the third quarter of 2016, mainly due to an increase in sales of higher-margin products.
Research and development (R&D) expenses were $8.1 million for the third quarter of 2017 compared with $5.5 million for the third quarter of 2016, with the increase due primarily to higher outside services expense related to CDX-6114, our lead candidate for the treatment of phenylketonuria (PKU), and increased costs associated with higher headcount, partially offset by the absence of amortization of intangibles. Selling, general and administrative (SG&A) expenses for the third quarter of 2017 were $8.0 million compared with $5.2 million for the third quarter of 2016, due primarily to an increase in legal fees and increased costs associated with higher headcount, partially offset by lower depreciation expense.
Net loss for the third quarter of 2017 was $10.2 million, or $0.21 per share, compared with net income for the third quarter of 2016 of $1.4 million, or $0.04 per basic share and $0.03 per diluted share. Non-GAAP net loss for the third quarter of 2017 was $8.2 million, or $0.17 per share, compared with non-GAAP net income for the third quarter of 2016 of $4.0 million, or $0.10 per basic share and $0.09 per diluted share. A reconciliation of GAAP to non-GAAP measures is provided below.
Year-to-date Financial Results
Total revenues for the nine months ended September 30, 2017 were $28.3 million compared with $38.9 million for the first nine months of 2016. The prior year period included the recognition of $20.4 million in milestone payments and deferred revenue from platform licensing deals with GSK and Merck. Total revenues for the first nine months of 2017 included $19.1 million in product sales, $8.3 million in R&D revenue and $0.8 million from the revenue-sharing arrangement with Exela.
Gross margin on product sales for the first nine months of 2017 was 44% compared with 33% for the first nine months of 2016, due to an increase in sales of higher-margin products.
R&D expenses for the first nine months of 2017 were $20.2 million compared with $16.3 million for the first nine months of 2016, with the increase primarily due to higher outside service fees related to CDX-6114 and increased costs associated with higher headcount. SG&A expenses for the first nine months of 2017 were $21.1 million compared with $18.5 million for the prior-year period, primarily due to an increase in legal expenses and increase in costs associated with higher headcount, partially offset by lower depreciation expense.
Net loss for the first nine months of 2017 was $24.0 million, or $0.53 per share, compared with a net loss for the first nine months of 2016 of $3.3 million, or $0.08 per share. Non-GAAP net loss for the first nine months of 2017 was $18.0 million, or $0.39 per share, compared with non-GAAP net income for the first nine months of 2016 of $4.5 million, or $0.11 per basic and diluted share.
Cash and cash equivalents as of September 30, 2017 were $23.8 million, compared with $19.2 million as of December 31, 2016.
Financial Outlook
Codexis affirms financial guidance for 2017, as follows:
Total revenues of $50 million to $53 million, which includes revenue from the Nestlé Health Science strategic collaboration announced in October 2017.
Product sales are expected to be between $25 million and $27 million, reflecting an increase of 63% to 76% over 2016.
Gross margin on product sales is expected to be between 40% and 43%.
Codexis expects fourth quarter operating expenses, which is the combined total of R&D and SG&A expenses, to be approximately $16 million, which is higher than our previous forecast due mainly to higher legal expenses. The guidance assumes expenses associated with the company’s accelerated development activities to initiate human trials for CDX-6114 in early 2018.
Non-GAAP Financial Measures
Consolidated financial information has been presented in accordance with GAAP as well as on a non-GAAP basis. On a non-GAAP basis, financial measures exclude non-cash items such as depreciation expense, intangible asset amortization expense and stock-based compensation expense. Non-GAAP financial measures presented are: non-GAAP net income or loss, non-GAAP net income or loss per share (basic and diluted), and non-GAAP operating expenses, including non-GAAP research and development expense and non-GAAP selling, general and administrative expense. Non-GAAP operating expenses exclude stock-based compensation expense, amortization of intangible assets and depreciation of fixed assets.
Codexis management uses these non-GAAP financial measures to monitor and evaluate its operating results and trends on an ongoing basis, and internally for operating, budgeting and financial planning purposes. Codexis management believes the non-GAAP information is useful for investors by offering them the ability to identify trends in what management considers to be Codexis’ core operating results and to better understand how management evaluates the business. These non-GAAP measures have limitations, however, because they do not include all items of expense that affect Codexis. These non-GAAP financial measures are not prepared in accordance with, and should not be considered in isolation of, or as an alternative to, measurements required by GAAP, and therefore these non-GAAP results should only be used for evaluation in conjunction with the corresponding GAAP measures. A description of the non-GAAP calculations and reconciliation to comparable GAAP financial measures is provided in the accompanying table entitled “Reconciliation of GAAP to Non-GAAP Financial Measures.”
Conference Call and Webcast
Codexis will hold a conference call and audio webcast today beginning at 4:30 p.m. Eastern time. A slide presentation featuring an updated chart of the company’s product pipeline to accompany the conference call commentary is available on the Investors section of the company’s website at www.codexis.com. The conference call dial-in numbers are 855-890-8665 for domestic callers and 720-634-2938 for international callers, and the passcode is 5797258. A live webcast of the call will be available on the Investors section of www.codexis.com.
A recording of the call will be available for 48 hours beginning approximately two hours after the completion of the call by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers. Please use the passcode 5797258 to access the recording. A webcast replay will be available on the Investors section of www.codexis.com for 30 days, beginning approximately two hours after the completion of the call.
About Codexis, Inc.
Codexis, Inc. is a leading protein engineering company that applies its technology to the development of biocatalysts for commercial manufacture of pharmaceuticals and fine chemicals, as well as the development of enzymes as biotherapeutics and for molecular diagnostics. Codexis’ proven technology enables implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable manufacturing. For more information, see www.codexis.com.
Forward-Looking Statements
To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including Codexis’ expectations regarding fourth quarter 2017 and 2017 total revenues, product sales, gross margin on product sales, and operating expenses, 2018 revenue growth, and its anticipated timeline to initiate human trials for CDX-6114 and associated expenditures. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Factors that could materially affect actual results include, among others: Codexis’ dependence on its licensees and collaborators; Codexis’ dependence on a limited number of products and customers in its biocatalysis business; potential adverse effects to Codexis’ business if its customers’ pharmaceutical or food products are not received well in the markets; risks, uncertainties and costs associated with the successful development of biotherapeutic candidates, including obtaining development partners for its biotherapeutic programs and progressing such programs to clinical trials and regulatory approvals; Codexis’ ability to develop and commercialize new products for the biocatalysis markets; Codexis’ dependence on a limited number of contract manufacturers for large-scale production of its enzymes; Codexis’ ability to deploy its technology platform in new market spaces, including the fine chemicals, therapeutics and in vitro molecular diagnostics markets; Codexis’ ability to comply with the terms of its credit facility and its associated debt service obligations; Codexis’ need for additional capital in the future in order to expand its business or to adjust for market conditions or strategic considerations, which may involve Codexis entering into equity offerings, debt financings, credit facilities and/or strategic collaborations; Codexis’ dependence on key personnel; risks associated with the patent litigation that Codexis initiated in February 2016; Codexis’ ability to establish and maintain adequate protection for intellectual property, trade secrets and other proprietary rights covering its technologies; and any claims by third parties that Codexis is infringing their intellectual property rights or other proprietary rights. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 9, 2017 and Form 10-Q filed August 9, 2017, including under the caption “Risk Factors” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Codexis Contacts:
Investors
LHA Investor Relations
Jody Cain, 310-691-7100
jcain@lhai.com

Financial Tables to Follow



Codexis, Inc.
Condensed Consolidated Statements of Opera

Chart looks great.

$CDXS recent news/filings

bullish 3.85
bull flag continuation

## source: finance.yahoo.com

Mon, 30 Nov 2015 13:40:00 GMT ~ New Information Reveals Opportunity in Volatility - Research on Strongbridge Biopharma, Pacific Mercantile Bancorp, Codexis and Exa Corp

[Accesswire] - NEW YORK, NY / ACCESSWIRE / November 30, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Strongbridge ...

read full: http://finance.yahoo.com/news/information-reveals-opportunity-volatility-research-134000165.html
*********************************************************

Thu, 26 Nov 2015 21:20:25 GMT ~ Breeze-Eastern Corp (BZC): Are Hedge Funds Right About This Stock?


read full: http://www.insidermonkey.com/blog/breeze-eastern-corp-bzc-are-hedge-funds-right-about-this-stock-390476/
*********************************************************

Tue, 24 Nov 2015 22:44:03 GMT ~ Is Southern National Banc. of Virginia, Inc (SONA) A Good Stock To Buy?


read full: http://www.insidermonkey.com/blog/is-southern-national-banc-of-virginia-inc-sona-a-good-stock-to-buy-386529/
*********************************************************

Tue, 24 Nov 2015 14:30:02 GMT ~ The Zacks Analyst Blog Highlights: Integrated Device Technology, ZAGG, MRV Communications, Codexis and Gigamon


read full: http://finance.yahoo.com/news/zacks-analyst-blog-highlights-integrated-143002671.html
*********************************************************

Tue, 24 Nov 2015 12:23:04 GMT ~ Codexis to Present at LD Micro Main Event

[at noodls] - REDWOOD CITY, Calif., Nov. 24, 2015 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, announces that management will ...

read full: http://www.noodls.com/view/731A58404F4EAD3FEA7CBBC2C682CB3E4E60D1D0
*********************************************************

$CDXS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CDXS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CDXS/company-info
Ticker: $CDXS
OTC Market Place: Not Available
CIK code: not found
Company name: Codexis, Inc.
Incorporated In:

Business Description:

$CDXS share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$CDXS extra dd links

Company name: Codexis, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CDXS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CDXS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CDXS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/news - http://finance.yahoo.com/q/h?s=CDXS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CDXS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CDXS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CDXS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Codexis%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Codexis%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Codexis%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CDXS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CDXS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CDXS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CDXS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CDXS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CDXS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CDXS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CDXS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CDXS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CDXS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CDXS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CDXS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CDXS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CDXS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CDXS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CDXS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CDXS



$CDXS DD Notes ~ http://www.ddnotesmaker.com/CDXS

$CDXS recent news/filings

bullish
quick trade
long term still fine

## source: finance.yahoo.com

Fri, 13 Mar 2015 17:04:10 GMT ~ CODEXIS INC Financials


read full: http://finance.yahoo.com/q/is?s=cdxs
*********************************************************

Mon, 09 Mar 2015 12:31:12 GMT ~ Codexis (CDXS) in Focus: Stock Falls 7.3% - Tale of the Tape


read full: http://finance.yahoo.com/news/codexis-cdxs-focus-stock-falls-123112280.html
*********************************************************

Mon, 09 Mar 2015 00:08:08 GMT ~ 10-K for Codexis, Inc.


read full: http://www.companyspotlight.com/routers/headline/27073/10004/6459806?cp_code=YAH1&1425859688
*********************************************************

Fri, 06 Mar 2015 11:28:21 GMT ~ CODEXIS INC Files SEC form 10-K, Annual Report


read full: http://biz.yahoo.com/e/150306/cdxs10-k.html
*********************************************************

Tue, 03 Mar 2015 22:13:33 GMT ~ Codexis posts 4Q profit


read full: http://sg.finance.yahoo.com/news/codexis-posts-4q-profit-221333733.html
*********************************************************

$CDXS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CDXS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CDXS/company-info
Ticker: $CDXS
OTC Market Place: Not Available
CIK code: not found
Company name: Codexis, Inc.
Incorporated In:

Business Description:

$CDXS share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value

$CDXS extra dd links

Company name: Codexis, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CDXS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CDXS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CDXS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/news - http://finance.yahoo.com/q/h?s=CDXS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CDXS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CDXS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CDXS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Codexis%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Codexis%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Codexis%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CDXS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CDXS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CDXS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CDXS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CDXS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CDXS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CDXS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CDXS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CDXS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CDXS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CDXS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CDXS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CDXS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CDXS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CDXS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CDXS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CDXS



$CDXS DD Notes ~ http://www.ddnotesmaker.com/CDXS

$CDXS DD Notes ~ http://www.ddnotesmaker.com/CDXS

bullish

$CDXS recent news/filings

## source: finance.yahoo.com

Wed, 03 Dec 2014 23:55:53 GMT ~ Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme Therapeutic Candidate for the Potential Treatment of Phenylketonuria (PKU) via Oral Administration

[at noodls] - REDWOOD CITY, Calif., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that it has ...

read full: http://www.noodls.com/view/BCB45A980239118C760CAE73EFF4A285AAF49112
*********************************************************

Wed, 03 Dec 2014 23:38:20 GMT ~ Codexis Uses Its CodeEvolver(R) Protein Engineering Platform Technology to Develop an Enzyme Therapeutic Candidate for the Potential Treatment of Phenylketonuria (PKU) via Oral Administration

[GlobeNewswire] - REDWOOD CITY, Calif. -- Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced that it has developed a novel enzyme therapeutic product ...

read full: http://finance.yahoo.com/news/codexis-uses-codeevolver-r-protein-233820703.html
*********************************************************

Tue, 25 Nov 2014 13:31:11 GMT ~ Codexis to Present at the LD Micro Main Event VII Conference on December 4

[at noodls] - REDWOOD CITY, Calif., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will provide ...

read full: http://www.noodls.com/view/30B4493C1D2BE9EB9D0610A8436632F42BCCEA13
*********************************************************

Tue, 25 Nov 2014 13:00:00 GMT ~ Codexis to Present at the LD Micro Main Event VII Conference on December 4

[GlobeNewswire] - REDWOOD CITY, Calif. -- Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will provide a corporate update at the LD Micro Main ...

read full: http://finance.yahoo.com/news/codexis-present-ld-micro-main-130000448.html
*********************************************************

Fri, 21 Nov 2014 19:45:00 GMT ~ Insider Trading Alert - ITG, CDXS And ARQL Traded By Insiders


read full: http://www.thestreet.com/story/12963765/1/insider-trading-alert--itg-cdxs-and-arql-traded-by-insiders.html?puc=yahoo&cm_ven=YAHOO
*********************************************************


$CDXS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$CDXS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CDXS/company-info
Ticker: $CDXS
OTC Market Place: Not Available
CIK code: not found
Company name: Codexis, Inc.
Incorporated In:

Business Description:


$CDXS share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$CDXS extra dd links

Company name: Codexis, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CDXS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CDXS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CDXS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/news - http://finance.yahoo.com/q/h?s=CDXS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CDXS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CDXS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CDXS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Codexis%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Codexis%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Codexis%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CDXS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CDXS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CDXS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CDXS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CDXS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CDXS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CDXS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CDXS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CDXS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CDXS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CDXS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CDXS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CDXS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CDXS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CDXS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CDXS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CDXS



$CDXS DD Notes ~ http://www.ddnotesmaker.com/CDXS

$CDXS DD Notes ~ http://www.ddnotesmaker.com/CDXS

bullish
price channel scan
http://stockcharts.com/school/doku.php?id=chart_school:chart_analysis:chart_patterns:price_channel_continuation
http://www.online-stock-trading-guide.com/channeling-stocks.html

$CDXS recent news/filings

## source: finance.yahoo.com

Tue, 21 Oct 2014 13:05:48 GMT ~ Codexis to Report Third Quarter 2014 Financial Results on November 4

[at noodls] - REDWOOD CITY, Calif., Oct. 21, 2014 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will report ...

read full: http://www.noodls.com/view/3C2D54B0D5958695233C2322D46B5E863DF3190A
*********************************************************

Tue, 21 Oct 2014 12:00:00 GMT ~ Codexis to Report Third Quarter 2014 Financial Results on November 4

[GlobeNewswire] - REDWOOD CITY, Calif. -- Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced it will report third quarter financial results after the ...

read full: http://finance.yahoo.com/news/codexis-report-third-quarter-2014-120000458.html
*********************************************************

Mon, 22 Sep 2014 20:47:14 GMT ~ CODEXIS INC Files SEC form 8-K, Change in Directors or Principal Officers


read full: http://biz.yahoo.com/e/140922/cdxs8-k.html
*********************************************************

Mon, 22 Sep 2014 12:00:00 GMT ~ Codexis Appoints Biotechnology Industry Veteran, Kathleen Glaub, to Board of Directors

[GlobeNewswire] - REDWOOD CITY, Calif. -- Codexis, Inc. , a leading developer of biocatalysts for the pharmaceutical and fine chemical industries, today announced the appointment of Kathleen Sereda Glaub to its board of ...

read full: http://finance.yahoo.com/news/codexis-appoints-biotechnology-industry-veteran-120000516.html
*********************************************************

Tue, 19 Aug 2014 17:04:10 GMT ~ CODEXIS INC Financials


read full: http://finance.yahoo.com/q/is?s=cdxs
*********************************************************


$CDXS charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$CDXS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CDXS/company-info
Ticker: $CDXS
OTC Market Place: Not Available
CIK code: not found
Company name: Codexis, Inc.
Incorporated In:

Business Description:


$CDXS share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$CDXS extra dd links

Company name: Codexis, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CDXS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CDXS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CDXS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/news - http://finance.yahoo.com/q/h?s=CDXS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CDXS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CDXS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CDXS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Codexis%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Codexis%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Codexis%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CDXS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CDXS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CDXS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CDXS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CDXS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CDXS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CDXS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CDXS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CDXS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CDXS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CDXS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CDXS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CDXS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CDXS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CDXS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CDXS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CDXS



$CDXS DD Notes ~ http://www.ddnotesmaker.com/CDXS

$CDXS recent news/filings

bullish

## source: finance.yahoo.com

Tue, 15 Jul 2014 18:11:00 GMT ~ Why Codexis (CDXS) Stock Hit a One-Year High Today


read full: http://www.thestreet.com/story/12774754/1/why-codexis-cdxs-stock-hit-a-one-year-high-today.html?puc=yahoo&cm_ven=YAHOO
*********************************************************

Tue, 15 Jul 2014 12:30:00 GMT ~ Codexis Inc Announces Technology Collaboration and License Agreement With GSK Call scheduled for 8:30 am ET today


read full: http://biz.yahoo.com/cc/3/143613.html
*********************************************************

Mon, 14 Jul 2014 21:41:06 GMT ~ Codexis Announces Technology Collaboration and License Agreement With GSK

[at noodls] - Codexis to Receive Up to $25 Million of Initial Payments, Plus Additional Milestone and Royalty Opportunities Codexis to Host a Conference Call on July 15, 2014 at 8:30 a.m. ET / 5:30 a.m. PT REDWOOD CITY, ...

read full: http://www.noodls.com/view/FEBC6AA6D0916039C3CC28E3FA876DA2C40AA213
*********************************************************

Mon, 14 Jul 2014 20:07:01 GMT ~ CODEXIS INC Files SEC form 8-K, Entry into a Material Definitive Agreement


read full: http://biz.yahoo.com/e/140714/cdxs8-k.html
*********************************************************

Mon, 14 Jul 2014 20:01:00 GMT ~ Codexis Announces Technology Collaboration and License Agreement With GSK

[GlobeNewswire] - Codexis to Receive Up to $25 Million of Initial Payments, Plus Additional Milestone and Royalty Opportunities

read full: http://finance.yahoo.com/news/codexis-announces-technology-collaboration-license-200100313.html
*********************************************************


$CDXS charts

basic chart ## source: stockcharts.com



basic chart ## source: eoddata.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$CDXS company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CDXS/company-info
Ticker: $CDXS
OTC Market Place: Not Available
CIK code: not found
Company name: Codexis, Inc.
Incorporated In:

Business Description:


$CDXS share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
$CDXS extra dd links

Company name: Codexis, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CDXS+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CDXS+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CDXS+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/news - http://finance.yahoo.com/q/h?s=CDXS+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CDXS/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CDXS+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CDXS
DTCC (dtcc.com): http://search2.dtcc.com/?q=Codexis%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Codexis%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Codexis%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CDXS
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CDXS&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CDXS
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CDXS+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CDXS+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CDXS
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CDXS
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CDXS+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CDXS/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CDXS+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CDXS.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CDXS
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CDXS/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CDXS/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CDXS
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CDXS
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CDXS:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CDXS
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CDXS



$CDXS DD Notes ~ http://www.ddnotesmaker.com/CDXS
gcnd

Get past 1.93-1.94 and could see some good movement.

Nice double bottom here.

$CDXS - $2.74 Change: +1.33 (+94.33%)

Codexis in License Pact With GlaxoSmithKline

4:18 PM ET 7/14/14 | Dow Jones
By Josh Beckerman

Codexis Inc. (CDXS), which develops bio-catalysts for pharmaceutical and chemical production, has granted GlaxoSmithKline PLC (GSK) a license to use its CodeEvolver protein technology.

The license lets Glaxo use Codexis' platform technology to develop enzymes for use in pharmaceutical and health-care products.

Codexis said it is eligible to receive up to $25 million over a period of about two years, $6 million of which will be paid upfront and $19 million that is subject to completion of technology transfer milestones.

The company could receive additional milestone payments of $5.75 million to $38.5 million per project, depending on successful application of the technology.

Shares were halted after hours.

Write to Josh Beckerman at josh.beckerman@wsj.com

Access Investor Kit for GlaxoSmithKline Plc

Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=GB0009252882

Access Investor Kit for Codexis, Inc.

Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=US1920051067

Access Investor Kit for GlaxoSmithKline Plc

Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=US37733W1053

Subscribe to WSJ: http://online.wsj.com?mod=djnwires



> Dow Jones Newswires

July 14, 2014 16:18 ET (20:18 GMT)

Copyright (c) 2014 Dow Jones & Company, Inc.

It's just a scan.. The chart has conflicting signals imo. Probably due to volume levels not being big board standard. GLTA whatever side of the tracks you are playing.

Though I don't see it yet, I wouldn't argue technically; but be aware of the legal battle with Dyadic imparing their forward movement including their relationship with Shell:

http://seekingalpha.com/article/1650942-codexis-continues-to-struggle-with-little-relief-in-sight?source=yahoo

Kind regards,
Minding

$CDXS > Technical bounce watch this week >

CDXS has hit the ol' scanner and has a fair chance of a bounce at these levels. Stocks that have declined this badly almost always retrace higher, bounce or dip some and come right back to this point before a further decline.
Contacting me with the fundamentals about the company does not change my criteria for scanning stocks.

If you just started shorting this stock, it might be a bad idea as this is totally oversold!



All of the "FASTLANE's BOMB's AWAY! SCANS" are of my own opinion and not to be used as investment advice.




$CDXS - Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=CDXS
$CDXS - Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=CDXS
$CDXS - Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=CDXS
$CDXS - Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=CDXS
$CDXS - Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=CDXS
$CDXS - Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=CDXS&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260




Regular Candlestick Chart: http://stockcharts.com/h-sc/ui?s=CDXS&p=D&b=3&g=0&id=p04384940601




Regular Candlestick Chart: http://stockcharts.com/h-sc/ui?s=CDXS&p=W&b=3&g=0&id=p04384940601







PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/CDXS


OTC Markets Company Info ~ http://www.otcmarkets.com/stock/CDXS/company-info
$CDXS - OTC Markets Charts ~ http://www.otcmarkets.com/stock/CDXS/chart
$CDXS - OTC Markets Quote ~ http://www.otcmarkets.com/stock/CDXS/quote
$CDXS - OTC Markets News ~ http://www.otcmarkets.com/stock/CDXS/news
$CDXS - OTC Markets Financials ~ http://www.otcmarkets.com/stock/CDXS/financials
$CDXS - OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/CDXS/short-sales
$CDXS - OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/CDXS/insider-transactions
$CDXS - OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/CDXS/research


Google Finance Summary ~ http://www.google.com/finance?q=CDXS
$CDXS - $CDXS - Google Finance News ~ http://www.google.com/finance/company_news?q=CDXS
$CDXS - Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=CDXS
$CDXS - Google Finance Financials ~ http://www.google.com/finance?q=CDXS&fstype=ii#
$CDXS - Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=CDXS
$CDXS - Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=CDXS&histperiod=weekly#


Y! < Company >
$CDXS - Y! Profile ~ http://finance.yahoo.com/q/pr?s=CDXS+Profile
$CDXS - Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=CDXS+Key+Statistics
$CDXS - Y! Headlines ~ http://finance.yahoo.com/q/h?s=CDXS+Headlines
$CDXS - Y! Summary ~ http://finance.yahoo.com/q?s=CDXS
$CDXS - Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=CDXS+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=CDXS+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/CDXS
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/CDXS
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=CDXS+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=CDXS+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=CDXS+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=CDXS+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=CDXS+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=CDXS+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=CDXS+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=CDXS+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=CDXS+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=CDXS+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=CDXS+Cash+Flow&annual


FINVIZ ~ http://finviz.com/quote.ashx?t=CDXS&ty=c&ta=0&p=d


CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=CDXS&exchange=US




$CDXS - Barchart Quote ~ http://barchart.com/quotes/stocks/CDXS?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/CDXS
Barchart Options Quotes ~ http://barchart.com/options/stocks/CDXS
Barchart Technical Chart ~ http://barchart.com/charts/stocks/CDXS&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/CDXS&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/CDXS
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=CDXS
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/CDXS
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/CDXS
Barchart News Headlines ~ http://barchart.com/news/stocks/CDXS
Barchart Profile ~ http://barchart.com/profile//CDXS
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=CDXS&view=key_statistics


OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=CDXS&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=CDXS&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=CDXS&MarketTicker=NYSE&Typ=S


Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/CDXS/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/CDXS/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/CDXS/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/CDXS/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/CDXS
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/CDXS/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/CDXS/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/CDXS/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/CDXS/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/CDXS/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/CDXS/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=CDXS&sid=1795093&framed=False


The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=CDXS


Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=CDXS


StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=CDXS&num1=567&cobrand=&mode=stock


StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=CDXS
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=CDXS


AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=CDXS&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8


Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=CDXS.PK&WTmodLOC=C4-Officers-5


StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=CDXS®ion=U


Search NASDAQ ~ http://www.nasdaq.com/symbol/CDXS
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/CDXS/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/CDXS/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/CDXS/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=CDXS&selected=CDXS
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=CDXS&selected=CDXS
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/CDXS/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/CDXS/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/CDXS/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/CDXS/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/CDXS/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/CDXS/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/CDXS/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/CDXS/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/CDXS/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/CDXS/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/CDXS/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/CDXS/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/CDXS/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/CDXS/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=CDXS&selected=CDXS
NASDAQ Financials ~ http://www.nasdaq.com/symbol/CDXS/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/CDXS/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/CDXS/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/CDXS/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/CDXS/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/CDXS/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/CDXS/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/CDXS/insider-trades/sells


The Motley Fool ~ http://caps.fool.com/Ticker/CDXS.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/CDXS/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/CDXS/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/CDXS/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/CDXS/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/CDXS/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/CDXS/Statements.aspx?source=icasittab0000009


MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=CDXS


YCharts ~ http://ycharts.com/companies/CDXS
YCharts Performance ~ http://ycharts.com/companies/CDXS/performance
YCharts Dashboard ~ http://ycharts.com/companies/CDXS/dashboard


InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=CDXS&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=CDXS&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=CDXS&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=CDXS


Zacks Quote ~ http://www.zacks.com/stock/quote/CDXS
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=CDXS
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=CDXS


Knobias ~ http://knobias.10kwizard.com/files.php?sym=CDXS


StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=CDXS


Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/CDXS/HOT_TOPIC.html


Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=CDXS&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=CDXS®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=CDXS®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=CDXS®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=CDXS®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=CDXS®ion=USA&culture=en-us


CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=CDXS


TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=CDXS


OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=CDXS&searcharea=e&image1.x=0&image1.y=0


Insidercow ~ http://www.insidercow.com/history/company.jsp?company=CDXS&B1=Search%21


Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=CDXS
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=CDXS&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=CDXS&start=1&max=10&searchResults=web&tag=web&sort=null


YouTube Symbol Search ~ http://www.youtube.com/results?search_query=CDXS


Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=CDXS


Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=CDXS


Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=CDXS

Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=CDXS
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=CDXS

Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=CDXS

Investorpoint ~ http://www.investorpoint.com/ enter "CDXS" and click search.

Hotstocked ~ http://www.hotstocked.com/ enter "CDXS" and click search.

Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=CDXS

Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=CDXS

DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=CDXS

SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=CDXS

OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=CDXS

Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "CDXS" and click search.

http://www.coordinatedlegal.com/SecretaryOfState.html

http://regsho.finra.org/regsho-Index.html

http://www.shortsqueeze.com/?symbol=CDXS&submit=Short+Quote%99

Yep... At least $3.50

Do you see an upside for this stock?
If volume picks up I see $4 near term.

$CDXS - Codexis and Chemtex Achieve Key Milestone in Commercial Development of Bio-Based Chemicals from Non-Food Cellulosic Biomass

http://finance.yahoo.com/news/codexis-chemtex-achieve-key-milestone-133600618.html

REDWOOD CITY, Calif. & TORTONA, Italy--(BUSINESS WIRE)--

Codexis (CDXS), a developer of engineered enzymes for pharmaceutical, biofuel and chemical production, and Chemtex, a leader in chemical engineering and renewable processes, today announced the successful scale-up in the production of CodeXol® detergent alcohols using cellulosic sugars. The scale-up was achieved at a 1,500 liter demonstration facility at Chemtex’s R&D complex in Tortona, Italy and is a key milestone in the ongoing effort initiated by the two companies to develop a fully integrated biomass to detergent alcohols technology. A combination of Chemtex’s commercially proven PROESA® cellulosic sugar technology and Codexis’ CodeXyme® 4X cellulase enzymes was used to produce cellulosic sugars from non-food biomass, while the CodeXol® detergent alcohol fermentation process technology – which includes Codexis’ proprietary microorganism strain – converted these cellulosic sugars to detergent alcohols.

Guido Ghisolfi, President of Chemtex, said, “While the PROESA® technology is proven at commercial scale for the production of cellulosic ethanol – as evidenced by the successful start-up of our commercial facility in Crescentino, Italy – this achievement is further proof that our platform cellulosic sugar technology is best-in-class for producing a broad range of bio-based chemicals using sustainable, non-food sources of biomass. It also validates our conviction that scaling up these technologies beyond the lab is key to enabling the learning curve towards commercial viability.”

John Nicols, President and CEO of Codexis, said, “This scale-up of CodeXol® detergent alcohols represents what we believe is the world’s first successful large scale effort to produce commercially relevant detergent alcohols from a cellulosic biomass feedstock. We believe this scale-up demonstrates the robustness and efficacy of our CodeXyme® cellulase enzymes and the ability of our CodeXol® detergent alcohol technology to produce detergent alcohols at commercial specification with the potential to decrease manufacturing costs below incumbent production costs.”

Detergent alcohols are used to manufacture surfactants, which are key, active cleaning ingredients in consumer products such as shampoos, liquid soaps and laundry detergents. The annual global market for detergent alcohols, which are currently manufactured from natural oils and fats and petrochemicals, is approximately $4 billion and is expected to reach $5.5 billion by 2020. Codexis and Chemtex initiated an effort in 2011 to produce these high-value chemicals from sustainable, low-cost and non-food sources of biomass, which has the potential to offer attractive production economics compared to incumbent production routes.

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical production. Codexis’ proven technology enables scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development – from research to manufacturing. For more information, see www.codexis.com.

About Chemtex

Chemtex is a global engineering and technology company wholly-owned by Italy’s Gruppo Mossi & Ghisolfi (“M&G”). Chemtex specializes in delivering value-added project solutions for its clients in the bio-fuels, renewable chemicals, energy, environmental, petrochemical, polymers and fibers industries. The company benefits from over 60 years of success in process development and commercializing hundreds of plants worldwide. Chemtex International Inc., its North American Headquarters, is located in Wilmington, N.C.

Chemtex is a leader in chemical engineering and renewable processes. It has engineered and constructed the world’s first commercial-scale cellulosic ethanol facility in Crescentino, Italy for Beta Renewables producing cellulosic ethanol from locally sourced cellulosic biomass using its PROESA® Process.

CDXS Video Chart 4/22/2013

http://www.qualitystocks.net/videocharts.php

Bottomed!

Shell Grants Codexis Rights to Commercialize Cellulase Enzymes for Biofuels

http://ir.codexis.com/phoenix.zhtml?c=208899&p=irol-newsArticle&ID=1730924&highlight=

... " Under the New Agreement, which is effective August 31, 2012, Shell has granted Codexis a royalty-bearing, non-exclusive license to develop, manufacture, use and sell cellulase enzymes developed under the companies’ Amended and Restated Collaborative Research Agreement, effective November 1, 2006 (the “Shell Research Agreement”). The scope of the New Agreement is worldwide, except Brazil, for enzymes used in the biofuels field. Codexis already has exclusive rights to commercialize its cellulase enzymes in other fields.

“Codexis has developed some of the most cost effective and competitively advantaged cellulase enzymes in the world. Securing the rights to market these enzymes to advanced biofuel companies outside of Shell is a major milestone for the company,” said John Nicols, President and CEO of Codexis. “We also remain focused on the Brazil market, where our discussions with Raízen continue regarding commercialization of our cellulase enzymes for second generation ethanol production.”

In exchange for these new rights, Codexis will be obligated to pay Shell a low single-digit percentage royalty on net sales of CodeXymeTM cellulase enzymes to customers other than Shell and its affiliates. Codexis will also be obligated to pay Shell a low single-digit percentage royalty on Codexis’ own use of cellulase enzymes in the biofuels field. Shell is also entitled to preferential pricing on purchases of cellulase enzymes from Codexis should the companies mutually agree to enter into a future supply arrangement." ...

Codexis, Inc. (CDXS - News), a developer of industrial enzymes to enable the cost advantaged production of biofuels, bio-based chemicals, and pharmaceutical intermediates, today announced that the FDA has approved a new process co-developed by Codexis for the manufacture of sitagliptin, the active pharmaceutical ingredient in Merck's Januvia®.

“FDA approval of this manufacturing process is a major milestone for Codexis,” said Peter Strumph, Interim Chief Executive Officer. “This is another example of how our directed evolution technology can deliver well controlled, cost advantaged commercial pharmaceutical, biofuel, or bio-based chemical production processes.”

The approved process, which won the Presidential Green Chemistry Award in 2010, is a more environmentally friendly and efficient production process than those used in the past. Specifically, it indicates the potential for improving the overall increase in yield of sitagliptin, while significantly decreasing waste byproducts.

Good luck! I will pass because I see a long, hard slog to attain any semblance of profitability. (The management change is but a sideshow, IMO.)

I agree and I added yesterday. I am a new shareholder.

I actually think this may turn out to be a big positive. The subtle message was the old CEO was the visionary who didn't have a clear plan to make money. From what was said I have almost no doubt that he was asked to leave. The new (interim) CEO stressed his operations background and implied controlling R&D. Its not clear to me what exactly the board is after and so I wouldn't be shocked if they put themselves up for sale. Though certainly predicting such things is very speculative and I did not invest with that expectation nor would I suggest others do!

after this latest plunge in share price, i did a little dd and came to the conclusion that the sell off was pure fear fueled panic sell based on nothing factual. that is where i come in scraping some shares up off the floor. got in at 3.77. thank you human emotion, never let me down. gonna make some money on this one. lots of room to bounce.

I thought the call was positive in that he dismissed the idea of something sinister going on behind closed doors. Might be a good time to average down...

Clean Technology Presentation Link
http://www.wsw.com/webcast/jeff67/cdxs/

Its just starting now (reply should be available immediately after). I like the sound of the new guy. It sounds as though he may be more than interim. Says he is more operationally oriented than R&D oriented. The CEO was booted by the board but the CFO left on his own to pursue another opportunity.

The Shell episode is somewhat bearish not only because Shell didn’t acquire CDXS outright, but also because Shell dealt with CDXS in a manner that ensures Shell won’t have to recognize CDXS profits and losses on its own income statement. I consider this a “tell” that Shell does not expect CDXS to be profitable anytime soon.

Forgot to thank you for the links.

I am not unsympathetic to your points about it being a lower margin business and thus far not having a clear path to profitability. My guess would be the company wasn't for sale when Shell did the deal.

The attraction to me is on valuation and basically getting a free call option (I figure cash+Pharma revenues values rest of company at nothing) on them getting their act to profitability together especially as the other segments start producing (non-R&D funding) revenues.

My modestly bearish take on CDXS (FWIW): #msg-72365310.

Codexis Has Historic Drop After CEO Resigns: San Francisco Mover
By Andrew Herndon - Feb 21, 2012 4:40 PM ET

Codexis Inc. (CDXS), the U.S. biotechnology company, had a record decline after Chief Executive Officer Alan Shaw departed and analysts downgraded its shares.

Codexis, which develops enzymes used in the production of biofuels, biochemicals and pharmaceuticals, declined 19 percent to $3.70 at the close in New York, the most since it began trading on April 22, 2010.

Shaw, who was president of the company since it was founded, will leave “to pursue other interests,” the Redwood City, California-based company said in a Feb. 17 statement. Peter Strumph, 47, senior vice president and business head of pharmaceuticals, was appointed interim CEO.

“Alan, in consultation with the board, decided that it was in the best interest of the company to turn over the reins at this time,” Wes Bolsen, chief marketing officer, said today by telephone. “The board decided that now was the best time to put in the leadership team that it’s going to take to move Codexis forward,”

Shaw will continue to serve as a special adviser to the board. His resignation follows the departure of Chief Financial Officer Robert Lawson, who left the company Jan. 24.

Lawson “chose to take another opportunity in the software industry, which is where he came from,” Bolsen said.

Michael Klein, a New York-based analyst with Sidoti & Co., downgraded the shares today to “neutral” from “buy” with a target price of $4. Codexis was also downgraded to “underweight” from “neutral” by Michael Cox, an analyst with Piper Jaffray & Co. in New York.
Ethanol Yeast

Codexis is working with a venture of Royal Dutch Shell Plc and Brazil’s Cosan SA Industria & Comercio on improved yeast strains to boost the output of mills that turn sugar cane into ethanol, technology it said in September it plans to sell at the end of this year.

The company also introduced new enzymes last year for converting biomass into sugars that can be used to make detergent alcohols it’s developing with Chemtex Inc.

“To what extent are these initiatives going to play out and what’s the timeline around when they play out?” Klein said. “That’s the uncertainty right now weighing on the stock.”

TEVA supported CDXS is down to $3.78..

~ $CDXS ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $CDXS ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=CDXS&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=CDXS&p=W&b=3&g=0&id=p54550695994



~ Barchart: http://barchart.com/quotes/stocks/CDXS?
~ OTC Markets: http://www.otcmarkets.com/stock/CDXS/company-info
~ Google Finance: http://www.google.com/finance?q=CDXS
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=CDXS#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=CDXS+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=CDXS
Finviz: http://finviz.com/quote.ashx?t=CDXS
~ BusyStock: http://busystock.com/i.php?s=CDXS&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=CDXS&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=CDXS
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=CDXS
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=CDXS
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=CDXS
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=CDXS
~ MarketWatch: http://www.marketwatch.com/investing/stock/CDXS/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=CDXS
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CDXS
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CDXS&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CDXS&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=CDXS&size=l&frequency=60&color=g


http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

Biotech Class Of 2010: IPOs Revisited

http://seekingalpha.com/article/317413-biotech-class-of-2010-ipos-revisited?source=yahoo

mark dec 7th on your calendar going to be a good day for cdxs!

price is going to increase


I noticed that on 11-30 late in the afternoon there was a presentation done by Codexix senior executives and the price increase came then the next day dec 1st steadily throughout the day if you look at the intradday chart on dec 1. so it seems like given it was only 274000 ish in volume it was word spreading slowly throughout the day

dec 7th is the analyst day and the news anticipation will hopefully cause the price to continue upward

they still had over 70 million in cash on the recent earnings announcement date and 35.9 million shares outstanding and revenues were increasing over same quarter last year and the numbers were not that disappointing and i believe that given their new relationships and developments ...raizen...cosan and shell, ethanol etc I believe the earnings are going to turn around

we saw recently PEIX as an ethanol producer turn around and rise from 40 cents to 1.85 in a very short period of time....when CDXS starts to show a turn around or even its anticipation now in the analyst world as the company gives future guidance , the price could rise from the lows which were extremely depressed levels..

8:46AM On The Wires (WIRES) : Codexis (CDXS) announced that one year after launch, its Codex Screening Kits are in use or evaluation in manufacturing process development at 50 pharmaceutical companies worldwide.

6. Codexis, Inc. (CDXS): Develops proprietary biocatalysts for pharmaceuticals and biofuels markets. Market cap of $159.0M. Estimated EPS growth over the next 5 years at 25.0%. Net institutional shares purchased over the current quarter at 1.3M, which is 6.21% of the company's 20.92M share float. The stock is a short squeeze candidate, with a short float at 7.02% (equivalent to 8.76 days of average volume). The stock is currently stuck in a downtrend, trading 6.54% below its SMA20, 22.5% below its SMA50, and 50.94% below its SMA200. The stock has performed poorly over the last month, losing 13.54%.

http://seekingalpha.com/article/299037-8-high-growth-biotech-stocks-being-bought-by-hedge-funds?source=yahoo

Codexis Presents Carbon Capture Update at DoE/NETL Conference
Two Million Fold Improvement in Enzyme Performance
s
Press Release Source: Codexis, Inc. On Wednesday August 24, 2011, 8:00 am EDT

REDWOOD CITY, Calif., Aug. 24, 2011 /PRNewswire/ -- Codexis, Inc. (Nasdaq:CDXS - News) presented important technical progress in its carbon capture program yesterday at the CO2 Capture Technology Meeting being sponsored this week by the U.S. Department of Energy/National Energy Technology Laboratory in Pittsburgh. Codexis, supported by a grant from the DoE's ARPA-E Recovery Act program, is using its patented CodeEvolver™ directed evolution technology to develop processes to reduce carbon dioxide emissions from coal-fired power plants.

The research program is based on development of customized carbonic anhydrase (CA) enzymes that could catalyze carbon capture under industrial conditions. Data showed CA performance has been improved by about two million fold over natural forms of the enzyme. Evolved CA enzymes are functional and stable in relatively inexpensive, energy efficient solvents for 24 hours at temperatures greater than 90 degrees C.

Use of carbon capture solvents with fully developed enzymes is expected to substantially reduce the costs and energy requirements to capture CO2 produced by coal-fired power plants. The data was presented by James Lalonde, Ph.D., Codexis' Vice President of Biochemistry and Engineering Research and Development. Codexis is jointly developing the technology with CO2 Solution, Inc., Quebec, Canada. (TSX-V:CST.v - News)

A 2011 NETL report estimated that coal-fired power plants account for roughly 37% of total U.S. CO2 emissions and that current technology to capture CO2 would reduce power generating capacity by 30%.

In May 2010, Codexis was selected to receive an ARPA-E Recovery Act program grant for up to $4.7 million from the U.S. Department of Energy for development of innovative technology to remove carbon dioxide from coal-fired power plant emissions. The grant was one of 37 research projects which the DoE said "could fundamentally change the way the country uses and produces energy."

Codexis is a clean technology company. Codexis develops optimized biocatalysts that make industrial processes faster, cleaner and more efficient. Codexis' technology is commercialized with leading global pharmaceutical companies and is in development for advanced biofuels with Shell, carbon capture and biobased chemicals. Wastewater treatment is a potential future market. For more information, visit www.codexis.com.

This press release contains forward-looking statements relating to Codexis' research in carbon capture technology and the ability of our carbon capture technology to substantially reduce the costs and energy requirements to capture CO2 produced by coal-fired power plants. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond our control and that could materially affect actual results. Factors that could materially affect actual results can be found in Codexis' Quarterly Report on Form 10-Q dated August 3, 2011 including under the caption "Risk Factors." Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Cleantech IPOs Revisited

http://seekingalpha.com/article/278456-cleantech-ipos-revisited?source=yahoo